Argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Argenx SE (XNAS-ARGX)
In STOCKS
Tap into 10 years of rich financial and market data, designed to support deep analysis and smarter decision making. Whether you’re tracking fiscal trends or monitoring market shifts, our platform gives you the insights in detail.
Need more than what’s standard? Submit a custom request and we’ll build a dataset that fits your exact needs. Whether it’s 10+ years of history, alternative data, or integration-ready formats just ask.
Available
Financial Data
Dive into detailed company financials — income statements, balance sheets, cash flow, and key ratios.
Explore comprehensive fiscal trends
Market Data
Access high-frequency market data — tick-level movements, hourly candles, and intraday trends or market snapshots.
Up to the tick market movements
Extended Data
Request tailored datasets — historical depth, alternative data sources, live data or custom formats.
Customized data sets to go beyond the basics
Got questions?
Feel free to reach out.